Guo et al. more widely evaluated the tumor microenvironment, as they incorporated CD3+ T cells in the tumor center, CD4+FOXP3+CD45RO+ regulatory T cells in the tumor center, and CD8+PD1+ T cells in the invasive margin to build a novel immune feature-based score called ‘neo-immunoscore’ to predict the OS of ccRCC patients after nephrectomy [17]. The gene discussed is CD4; the disease is neoplasm.